Real‐World Use of Avatrombopag in Children and Adolescents With Immune Thrombocytopenia
Pediatric Blood & Cancer · 2026
DOI: 10.1002/pbc.32143 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Emily M Harris und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Thiazoles, Receptors, Thrombopoietin, Thiophenes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Avatrombopag, a second‐generation thrombopoietin receptor agonist (TPO‐RA), is approved for treatment of chronic immune thrombocytopenia (ITP) in adults and has been studied in a Phase 3 trial in pediatric ITP. The reported efficacy, oral administration, safety profile, and lack of dietary restrictions are appealing treatment characteristics for children. Data on real‐world use in children are limited.
Methods
This multicenter cohort study included patients diagnosed with ITP at age < 21 years treated with avatrombopag. Clinical features were collected from electronic medical records. Overall platelet response was defined as platelet count ≥ 30 × 10 9 /L and doubling from baseline.
Results
A total of 58 pediatric patients were treated with avatrombopag. Median time from diagnosis to treatment initiation was 4.6 years, with a median of 3 (range 0–11) prior treatments. Overall platelet response was 89.3% with similar response in primary and secondary ITP. Most patients achieved a response on the initial dose. Response rates did not differ by age at treatment initiation. Median time to platelet response was 13.5 days. High‐grade bleeding scores were lower after initiation of treatment. Most patients (62%) switched from another TPO‐RA to avatrombopag. Response to prior TPO‐RA was associated with higher likelihood of response to avatrombopag (OR 15.00, 95% CI 1.824–187.7, p = 0.017). Of 12 patients with no response to prior TPO‐RA, 8 responded to avatrombopag. Adverse effects were rare.
Conclusions
In this real‐world study, avatrombopag was highly effective at both improving platelet counts and reducing bleeding in children with ITP, even in patients with secondary ITP or who had failed other TPO‐RAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston, Texas, USA.
- Texas Children's Cancer and Hematology Center, Houston, Texas, USA.
- Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Emily M Harris, Praharsha Konde, Rachael F Grace
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Harris, E. M., Montcrieff, C., O'Farrell, C., Konde, P., Lambert, M. P., Grimes, A. B., & Grace, R. F. (2026). Real‐World Use of Avatrombopag in Children and Adolescents With Immune Thrombocytopenia. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.32143
Vancouver
Harris EM, Montcrieff C, O'Farrell C, Konde P, Lambert MP, Grimes AB, et al. Real‐World Use of Avatrombopag in Children and Adolescents With Immune Thrombocytopenia. Pediatric Blood & Cancer. 2026. doi:10.1002/pbc.32143
BibTeX
@article{Harris2026,
author = {Harris, Emily M and Montcrieff, Caitlin and O'Farrell, Candelaria and Konde, Praharsha and Lambert, Michele P and Grimes, Amanda B and Grace, Rachael F},
title = {Real‐World Use of Avatrombopag in Children and Adolescents With Immune Thrombocytopenia},
journal = {Pediatric Blood & Cancer},
year = {2026},
doi = {10.1002/pbc.32143}
}
EUVIMED